Amin company Rebean ® (Eloyu mono-resistant injection) approved for wider indications

recently, AmgenCompany(http://announced that its Rebean ® (Eloyu mono-injection) was approved on November 22, 2019 for a wider range of indications, becoming the first in China to be approved for adult primary hypercholesterolemia (including heterogenous family hypercholesterolemia) and mixed blood lipid disorders patients pcSK9 inhibitorsAbout Eloyu monolithEloyu monosyac is an innovative fat-loweringdrug(http://that increases the number of LDLLs that can clear LDL from the blood by inhibiting the binding of pre-protein-converted enzyme serotonin/Kexin 9 type (PCSK9) to LDL receptors (LDL)this approval further expands the indications of Eloyo monoantigen, which can be used as a dietary aid to the treatment of adult primary hypercholesterolemia (hybrid family and non-family) or mixed lipid disorders to reduce LDL-C levels: including in the largest acceptance of the In patients whose toler-resistant doseof statin therapy is still unable to meet the LDL-C target, he is not treated with statins, or in combination with statins and other lipid-lowering therapies, or in patients whose statins are intolerant or contraindicated, to be taken alone or in combination with other lipid-lowering therapiesThe ® of Reberian was approved by the NationalDrug(http://Supervisory Authority on July 31, 2018 for pure-bond family hypercholesterolemia in adults or adolescents over 12 years of ageapproved on 28 January 2019 for use in adult patients with atherosclerosis cardiovascular disease to reduce the risk of myocardial infarction, stroke, and coronary blood reconstruction